Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT
ENTERING INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH ROCHE FOR NOVEL DLL3 ADC

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") is pleased to announce that the Company, and its wholly-owned subsidiaries, including Innovent Biologics (Suzhou) Co. Ltd., Fortvita Biologics (Singapore) Pte. Ltd. and Fortvita Biologics Limited (together with the Company, the "**Group**") on the one hand, and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together with F. Hoffmann-La Roche Ltd, "**Roche**") on the other hand, entered into a collaboration and exclusive license agreement (the "**Agreement**"), pursuant to which the Group has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009, a novel DLL3-targeted antibody drug conjugate ("**ADC**") candidate. IBI3009 has already obtained investigational new drug (IND) approvals in Australia, China and the U.S., with the first patient for the Phase 1 study dosed in December 2024. This collaboration aims to bring innovative treatment options to patients with advanced small cell lung cancer (SCLC).

Under the Agreement, the Group and Roche will jointly focus on the early-stage development of this ADC candidate, after which Roche will take over full development. The Group will receive an upfront payment of US$80 million and is eligible to receive milestone payments of up to US$1 billion comprising development and commercial milestones, along with tiered royalties on net sales of up to mid-teens percentage.

About IBI3009

IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly SCLC and other neuroendocrine tumors. Developed leveraging the Group's proprietary novel topoisomerase 1 inhibitor (TOPO1i) platform, IBI3009 is one of the leading and potentially best-in-class DLL3-targeting ADCs. IBI3009 has shown encouraging anti-tumor activity in multiple tumor-bearing mouse models, particularly in chemo-resistant tumor types, and has demonstrated a favorable safety profile.

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Forward-Looking Statements

This announcement may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
January 2, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent non-executive Directors.